Information  X 
Enter a valid email address

Hikma Pharmaceutical (HIK)

  Print          Annual reports

Monday 15 March, 2021

Hikma Pharmaceutical

Director/PDMR Shareholding

RNS Number : 2787S
Hikma Pharmaceuticals Plc
15 March 2021
 

 

Hikma Pharmaceuticals PLC - EIP B Vesting

LONDON, 15 March 2021: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 12 March 2019 under the 2014 Executive Incentive Plan ("EIP") Element B.  

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 61,666

d)

Aggregated information

Volume

Price 

Total

 

 

61,666

£0.00

£0.00

e)

Date of the transaction

12 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

Siggi Olafsson

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Sigurdur Olafsson

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B.  Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 35,513

 

Price(s): £22.057

Volume(s): 31,794

d)

Aggregated information

Volume

Price 

Total

 

 

67,307

£22.057

£701,280.26

e)

Date of the transaction

12 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 42,572

d)

Aggregated information

Volume

Price

-     Total

 

 

42,572

£0.00

£0.00

e)

Date of the transaction

12 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 32,027

d)

Aggregated information

Volume

Price 

Total

 

 

32,027

£0.00

£0.00

e)

Date of the transaction

12 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 17,091

d)

Aggregated information

Volume

Price

Total

 

 

17,091

£0.00

£0.00

e)

Date of the transaction

12 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 27,193

d)

Aggregated information

Volume

Price 

Total

 

 

27,193

£0.00

£0.00

e)

Date of the transaction

12 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 25,089

d)

Aggregated information

Volume

Price 

Total

 

 

25,089

£0.00

£0.00

e)

Date of the transaction

12 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

 

Brian Hoffmann

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Brian Hoffmann

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B.  Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 8,435

 

Price(s): £22.057

Volume(s): 7,552

d)

Aggregated information

Volume

Price 

Total

 

 

15,987

£22.057

£166,574.46

e)

Date of the transaction

12 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

 

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B.  Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 7,626

 

Price(s): £22.057

Volume(s): 6,828

d)

Aggregated information

Volume

Price 

Total

 

 

14,454

£22.057

£150,605.20

e)

Date of the transaction

12 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

 

Henriette Nielsen

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Henriette Nielsen

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B.  Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 4,627

 

Price(s): £22.057

Volume(s): 5,275

d)

Aggregated information

Volume

Price 

Total

 

 

9,902

£22.057

£116,350.68

e)

Date of the transaction

12 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760

15 March 2021

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBBGDXSDBDGBU

a d v e r t i s e m e n t